Description
Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor originally developed by Glaxo and subsequently developed by Lilly ICOS (marketed as Cialis and Adcirca) as one of the most extensively-studied members of the PDE5 inhibitor pharmaceutical class. Tadalafil is characterized in academic and clinical research literature for its distinctive pharmacokinetic profile — a significantly longer plasma half-life (~17.5 hours) compared to sildenafil (~4 hours) and vardenafil (~4-5 hours) — which has established it as a research reference compound for extended-duration PDE5 inhibitor pharmacology research. This 5mg oral capsule format matches the standard low-dose daily research dosing established in the extensive PDE5 inhibitor research literature (also corresponding to the FDA-approved Cialis Daily 5mg formulation). Tadalafil has been investigated across multiple research literature streams: PDE5 pharmacology and cGMP signaling cascade research, cardiovascular research (particularly pulmonary arterial hypertension, where tadalafil is approved as Adcirca), endothelial function research, benign prostatic hyperplasia research, and comparative research versus other PDE5 inhibitors (sildenafil, vardenafil, avanafil). The oral capsule format uses microcrystalline cellulose (MCC) as the standard capsule excipient in a gelatin capsule shell. The compound is offered here strictly for laboratory research applications investigating PDE5 pharmacology and comparative research within the PDE5 inhibitor research compound class.
Benefits (Research Focus)
• PDE5 pharmacology research — studied as one of the most-characterized selective phosphodiesterase-5 inhibitor research compounds in the academic literature
• Extended half-life PDE5 research — investigated as the extended-duration reference compound in the PDE5 inhibitor class (~17.5 hour half-life)
• cGMP signaling research — explored for cGMP signaling cascade research and downstream vascular smooth muscle pharmacology
• Comparative PDE5 inhibitor SAR — examined alongside sildenafil, vardenafil, and avanafil for comparative PDE5 inhibitor structure-activity relationship studies
• Endothelial function research — researched for endothelial function endpoints in vascular research models
What Researchers Look At
• PDE5 enzyme inhibition kinetics and selectivity profiles versus PDE1, PDE2, PDE3, PDE4, PDE6 isoforms
• cGMP accumulation and downstream vascular smooth muscle relaxation endpoints in research models
• Comparative pharmacokinetic profiles versus sildenafil (~4 hr t½), vardenafil (~4-5 hr t½), and avanafil (~5 hr t½)
• Endothelial function markers and vascular research endpoints
• Pulmonary arterial hypertension research endpoints (tadalafil is approved as Adcirca for this indication)
Quick Specs
• Form: Gelatin capsule
• Strength: 5 mg tadalafil per capsule
• Quantity: 30 capsules per bottle
• Total Tadalafil per Bottle: 150 mg
• Other ingredients: Microcrystalline cellulose (MCC, excipient), gelatin capsule shell
• Appearance: Standard gelatin capsule presentation
• Purity: ≥99%
• Identity: MS-verified (per COA)
• Storage: Protect from light
Identity Basics
• Compound: Tadalafil
• Synonyms: IC-351 (original development code); Cialis (Lilly brand name reference); Adcirca (Lilly brand name for pulmonary hypertension indication); selective PDE5 inhibitor research compound
• Class: Synthetic small molecule; selective phosphodiesterase-5 (PDE5) inhibitor; pyrazino-pyrido-indole-dione chemistry class; oral PDE5 research compound
• Mechanism: Selective competitive inhibitor of PDE5 enzyme; increases cGMP by preventing cGMP hydrolysis
• Originator: Originally developed by Glaxo (as GR-30040X); subsequently licensed to ICOS Corporation; developed as IC-351 by Lilly ICOS partnership
• Plasma half-life: ~17.5 hours (significantly longer than sildenafil ~4 hours or vardenafil ~4-5 hours)
• Formula: C22H19N3O4
• Molecular Weight: ~389.40 g/mol
• CAS: 171596-29-5
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications in this presentation.
- Serious cardiovascular drug interactions: PDE5 inhibitors have documented severe interactions with nitrates (nitroglycerin, isosorbide) and alpha-blockers, with potential for life-threatening hypotension. Individuals with cardiovascular conditions should not use PDE5 inhibitor products without medical supervision.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the capsule label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each batch, regardless of what the label or product image indicates.
Third-Party Testing
• [COA links for the Tadalafil 5mg × 30 capsule batch to be added once analytical testing is complete]
